Sun Pharma's Obesity Breakthrough: A New Era in Weight Management

Sun Pharmaceutical Industries Limited will change the way it treats obesity with its experimental medication GL0034 (Utreglutide). Recent research has yielded optimistic findings, proving substantial weight loss and cholesterol improvement in obese patients. The drug administered weekly, in addition to decreasing weight, increased insulin sensitivity and glucose control. Sun Pharma hopes to market this new treatment in the next four to five years, possibly as soon as 2029. With the international obesity epidemic growing by the day, GL0034 has the potential to be a vital agent in the fight against this universal health epidemic, helping millions of people with weight control issues.
Sources: Reuters, Business Today, MarketScreener